Monte Rosa Therapeutics is Switzerland-based biotech founded in 2018, specializing in cancer therapeutics that modulate protein degradation pathways. The company uses AI-powered deep neural net the identify therapeutically relevant protein targets that may be targeted with molecular glue degraders and designs the molecules that can be optimized towards high potency and selectivity. Their proprietary platform QuEEN (Quantitative and Engineered Elimination of Neosubstrates) aims to uncover the molecular interactions between degrons on the surface of therapeutically relevant proteins and E3 ligases. Degrons are elements on proteins that act as ubiquitin ligase recognition signals for protein degradation by the UPS.